Sanofi

In 2004 was created Sanofi, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Paris. The venture was found in Europe in France.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2019. Comparing to the other companies, this Sanofi performs on 11 percentage points less the average number of lead investments. The increased amount of exits for fund were in 2019. The typical startup value when the investment from Sanofi is 500 millions - 1 billion dollars. The fund is generally included in less than 2 deals every year. Speaking about the real fund results, this Corporate Investor is 25 percentage points more often commits exit comparing to other organizations.

We also calculated 28 valuable employees in our database.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Sanofi, startups are often financed by Third Rock Ventures, Themelios Ventures, Research Corporation Technologies. The meaningful sponsors for the fund in investment in the same round are Casdin Capital, Virginia Tech Carilion (VTC) Innovation Fund, Verily. In the next rounds fund is usually obtained by VT Ventures, Sequoia Capital China, Redmile Group.

The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight BioNtech, Icosavax, Aetion. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Life Science, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

Notable deals

Review

• No reviews are submitted yet.